ZURA · Zura Bio Ltd - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $14.75M | - | $11.95M | $8.70M | $10.47M | - | $6.03M | $5.54M | $3.59M | - |
| SG&A | $10.75M | - | $7.57M | $9.36M | $8.78M | - | $13.29M | $6.22M | $4.79M | - |
| Total Operating Expenses | $25.50M | - | $19.52M | $18.06M | $19.25M | - | $19.32M | $11.76M | $8.38M | - |
| D&A | $16.0K | - | - | - | $9.0K | - | - | - | - | - |
| Operating Income | ($25.50M) | - | ($19.52M) | ($18.06M) | ($19.25M) | - | ($19.32M) | ($11.76M) | ($8.38M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | - | - |
| Income Tax | $0 | - | - | - | - | - | - | - | - | - |
| Net Income | ($24.22M) | - | ($18.04M) | ($15.99M) | ($17.44M) | - | ($20.70M) | ($10.33M) | ($7.75M) | - |
| EPS - Basic | ($0.22) | - | ($0.21) | ($0.17) | ($0.19) | - | ($0.26) | ($0.17) | ($0.02) | - |
| EPS - Diluted | ($0.22) | - | ($0.21) | ($0.17) | ($0.19) | - | ($0.26) | ($0.17) | ($0.02) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $225.59M | $109.41M | $139.02M | $154.49M | $170.57M | $176.50M | $188.22M | $188.44M | $89.82M | $99.80M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $2.08M | $1.28M | $3.27M | $1.21M | $1.25M | $733.0K | $1.01M | $990.0K | $1.49M | $2.75M |
| Current Assets | $227.00M | $112.31M | $142.29M | $156.99M | $171.69M | $178.74M | $188.97M | $189.47M | $90.47M | $100.84M |
| Total Assets | $228.64M | $113.95M | $143.94M | $157.81M | $172.50M | $179.53M | $189.07M | $189.50M | $90.48M | $100.84M |
| Current Liabilities | $11.74M | $12.41M | $25.49M | $18.70M | $21.09M | $19.51M | $18.24M | $15.07M | $14.67M | $20.30M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $11.74M | $12.41M | $25.49M | $18.70M | $21.09M | $19.51M | $18.24M | $17.44M | $16.27M | $21.29M |
| Stockholders' Equity | $216.90M | $101.54M | $108.24M | $125.91M | $138.20M | $146.81M | $153.05M | $156.52M | $61.01M | $59.33M |
| Retained Earnings | ($248.77M) | ($224.55M) | ($207.37M) | ($189.33M) | ($173.34M) | ($155.90M) | ($142.27M) | ($121.57M) | ($111.24M) | ($103.49M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($18.92M) | - | - | - | ($11.06M) | - | - | - | ($4.98M) | - |
| Investing Cash Flow | ($13.0K) | - | - | - | ($49.0K) | - | - | - | ($5.01M) | - |
| Financing Cash Flow | $135.12M | - | - | - | $5.18M | - | - | - | - | - |
| CapEx | $13.0K | - | - | - | $49.0K | - | - | - | $7.0K | - |
| Free Cash Flow | ($18.94M) | - | - | - | ($11.11M) | - | - | - | ($4.99M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | 0.78 | - | - | - | 0.64 | - | - | - | 0.64 | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -10.6% | - | -12.5% | -10.1% | -10.1% | - | -10.9% | -5.5% | -8.6% | - |
| Return on equity | -11.2% | - | -16.7% | -12.7% | -12.6% | - | -13.5% | -6.6% | -12.7% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 19.33 | 9.05 | 5.58 | 8.40 | 8.14 | 9.16 | 10.36 | 12.57 | 6.17 | 4.97 |
| Quick ratio | 19.33 | 9.05 | 5.58 | 8.40 | 8.14 | 9.16 | 10.36 | 12.57 | 6.17 | 4.97 |
| Cash ratio | 19.21 | 8.82 | 5.45 | 8.26 | 8.09 | 9.04 | 10.32 | 12.50 | 6.12 | 4.92 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | - | - |
| Equity multiplier | 1.05 | 1.12 | 1.33 | 1.25 | 1.25 | 1.22 | 1.24 | 1.21 | 1.48 | 1.70 |
| Liabilities / Assets | 0.05 | 0.11 | 0.18 | 0.12 | 0.12 | 0.11 | 0.10 | 0.09 | 0.18 | 0.21 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | - | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 3.1x | - | 3.8x | 0.8x | 0.9x | - | 2.3x | 1.7x | 2.0x | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | -32.4% | - | -1.0% | -53.6% | -129.8% | - | -89.6% | 65.3% | -8.6% | - |
| Net income growth (YoY) | -38.9% | - | 12.9% | -54.8% | -125.1% | - | -150.3% | 69.6% | 19.2% | - |
| EPS growth (YoY) | -15.8% | - | 19.2% | 0.0% | -850.0% | - | -44.4% | 87.0% | 99.3% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | -70.4% | - | - | - | -122.7% | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | 56.9% | -30.8% | -29.3% | -19.6% | 126.5% | 147.5% | 142.1% | 127.1% | 119.0% | - |
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Zura Bio Ltd against the 5 most active filers in the same SIC group.